Instructions
Please read this page carefully. You will need to scroll down this page and ensure that you have read the learning objectives, accreditation information, and potential conflicts of interest disclosures for the authoring faculty. Please check the box to agree to the terms of understanding and click the "Start Module" button on the bottom of the page to begin your learning activity.

Learning Objectives
After successful completion of this activity, participants will be able to:

• Restate expert opinion regarding recent changes to the standard of care for patients with Crohn’s Disease
• Recall the mechanism of action of biologic therapies and how they interfere with the cascade of biochemical events involved in the inflammatory response.
• Advise a young patient hospitalized with active Crohn’s Disease on the risks and benefits of early use of biologic therapies.
• Counsel a middle-aged patient who has undergone ileocolonic resection for Crohn’s Disease on the risks and benefits of antiTNF therapy to prevent postoperative recurrence
• Evaluate recent clinical research advances as they apply to patients with Crohn’s Disease, and provide a higher level of care.

Accreditation
This learning activity has been designated for 2.00 AMA PRA Category 1 Credits™. Physicians should only claim credits commensurate with the extent of their participation in this activity.

Target Audience
This activity is intended for gastroenterologists, internists, nurses, surgeons, clinical researchers, and other health care professionals with an interest in the treatment of patients with Crohn’s Disease.

Disclosure Statements
To view the Disclosure Statements, please click here.